Stay updated with breaking news from Novel Factor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study participants may transition from the rivaroxaban arm to abelacimab in an extension study
Published: May 06, 2021 SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc.. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We made significant progress across our Protease Medicines platform, specifically in our complement and hemostasis programs. We are preparing to initiate an observational trial in patients who have diseases related to CFI deficiency in mid-year 2021 to support our SQ enhanced CFI development candidate CB 4332 that will enter the clin...